Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy
Status:
Completed
Trial end date:
2020-10-16
Target enrollment:
Participant gender:
Summary
The use of sodium glucose co-transporter 2 inhibitors (SGLT2i) has been associated with
increased serum ketone levels. However, most previous studies included subjects who were
either insulin or even drug naïve with relatively short duration of diabetes. It is well
known that insulin deficiency increases the risk of developing ketoacidosis with SGLT2
inhibitors. Moreover, since the glucose-lowering effect of SGLT2 inhibitors is at its maximum
at 3 to 6 months after use, the extent of increase in serum ketone levels and its clinical
relevance with chronic use of SGLT2 inhibitors, especially among insulin-treated patients
that often have longer duration of diabetes and potentially more insulin deficient than those
who are insulin naive, have not been clearly defined. Therefore, the investigators perform
this randomised study to evaluate the effect of SGLT2 inhibitors on serum ketone levels among
Chinese patients with T2DM inadequately controlled with insulin therapy.